Pfizer Inc (PFE)
25.42
-0.27
(-1.05%)
USD |
NYSE |
Apr 17, 16:00
25.42
0.00 (0.00%)
Pre-Market: 20:00
Pfizer SG&A Expense (Quarterly): 4.575B for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 4.575B |
September 30, 2023 | 3.281B |
June 30, 2023 | 3.497B |
March 31, 2023 | 3.418B |
December 31, 2022 | 4.645B |
September 30, 2022 | 3.391B |
June 30, 2022 | 3.048B |
March 31, 2022 | 2.593B |
December 31, 2021 | 4.104B |
September 30, 2021 | 2.899B |
June 30, 2021 | 2.923B |
March 31, 2021 | 2.777B |
December 31, 2020 | 3.739B |
September 30, 2020 | 2.658B |
June 30, 2020 | 2.659B |
March 31, 2020 | 2.541B |
December 31, 2019 | 2.616B |
September 30, 2019 | 3.26B |
June 30, 2019 | 3.511B |
March 31, 2019 | 3.339B |
December 31, 2018 | 2.164B |
September 30, 2018 | 3.494B |
June 30, 2018 | 3.542B |
March 31, 2018 | 3.412B |
December 31, 2017 | 4.555B |
Date | Value |
---|---|
September 30, 2017 | 3.504B |
June 30, 2017 | 3.43B |
March 31, 2017 | 3.315B |
December 31, 2016 | 4.43B |
September 30, 2016 | 3.559B |
June 30, 2016 | 3.471B |
March 31, 2016 | 3.385B |
December 31, 2015 | 5.048B |
September 30, 2015 | 3.27B |
June 30, 2015 | 3.386B |
March 31, 2015 | 3.104B |
December 31, 2014 | 3.981B |
September 30, 2014 | 3.556B |
June 30, 2014 | 3.52B |
March 31, 2014 | 3.04B |
December 31, 2013 | 4.152B |
September 30, 2013 | 3.395B |
June 30, 2013 | 3.591B |
March 31, 2013 | 3.217B |
December 31, 2012 | 4.337B |
September 30, 2012 | 3.491B |
June 30, 2012 | 3.665B |
March 31, 2012 | 3.968B |
December 31, 2011 | 3.946B |
September 30, 2011 | 4.457B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.541B
Minimum
Mar 2020
4.645B
Maximum
Dec 2022
3.270B
Average
3.26B
Median
Sep 2019
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 2.274B |
Gilead Sciences Inc | 1.608B |
Johnson & Johnson | 5.81B |
Viking Therapeutics Inc | 8.783M |
Moderna Inc | 470.00M |